Asimov
The genetic-design platform for biotech.
About Asimov
Software-defined biology — cellular design, modeling, and manufacturing for therapeutic and industrial biotech.
Pitch deck breakdown
How Asimov would pitch themselves.
Target customer
Biotech — the core audience Asimov's product is built around.
Problem they solve
Software-defined biology — cellular design, modeling, and manufacturing for therapeutic and industrial biotech. The category has historically been served by tools that miss the modern workflow this product is built around.
Key differentiator
Asimov differentiates on the genetic-design platform for biotech. Backed by Canaan + Andreessen Horowitz, $202M+ raised — the company has resources + validation to compound this thesis. Founded by Alec Nielsen + team.
Go-to-market strategy
Growth-stage GTM — multi-channel revenue motion (direct enterprise sales, channel partnerships, marketplace listings). Vertical specialisation + verticalised AE teams targeting enterprise + mid-market.
Company facts
- Category
- Other
- Funding stage
- Series B
- Total raised
- $202M+
- Founded
- 2017
- Team size
- 51-200
- HQ
- Boston
- Country
- United States
- Website
- asimov.com
Founders of Asimov
- Alec Nielsen
- Christopher Voigt
- Raja Srinivas
- Douglas Densmore
Investors backing Asimov
- Canaan
- Andreessen Horowitz
Frequently asked questions
What does Asimov do?
Software-defined biology — cellular design, modeling, and manufacturing for therapeutic and industrial biotech.
Where is Asimov based?
Asimov is based in Boston, United States.
When was Asimov founded?
Asimov was founded in 2017.
How much has Asimov raised?
Asimov has raised $202M+ in their Series B round.
Who founded Asimov?
Asimov was founded by Alec Nielsen, Christopher Voigt, Raja Srinivas, Douglas Densmore.
Who has invested in Asimov?
Asimov is backed by Canaan, Andreessen Horowitz.